The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Sapina-Beltran, E
- Torres, G
- Barbe, F
Grupos
Abstract
Purpose of ReviewThis review seeks to present an overview of the recently found association between refractory hypertension (RfH) and obstructive sleep apnoea (OSA).Recent FindingsRfH was recently defined as an extreme phenotype of resistant hypertension characterized by the lack of blood pressure control despite using 5 antihypertensive drugs at optimal doses. Current data support that the pathophysiological pathway of both types of hypertension is different. The main mechanism involved in resistant hypertension is fluid retention whereas in the case of RfH is the sympathetic over-activity. OSA is now recognized as a cause of hypertension (especially in the case of difficult-to-treat hypertension). It seems that the biological mechanism linking OSA and arterial hypertension is the sympathetic over-activity related to the respiratory events (apnoeas and hypopnoeas) during the night. So, it is not surprising that, although the literature is scarce, some studies have found a very high prevalence of OSA and an excess of sympathetic activity in patients with RfH. Finally, a very recent study demonstrated that continuous positive airway pressure (CPAP) treatment, which controls sympathetic activation in OSA patients, achieves very significant reductions in blood pressure levels in RfH patients, even greater than in those with resistant (non-refractory) hypertension.SummaryThe prevalence of OSA in patients with RfH is very high. CPAP treatment achieves a clinically significant reduction in blood pressure levels in those patients with RfH (especially in night readings). Patients with RfH must be sent to a sleep unit for a study.
Datos de la publicación
- ISSN/ISSNe:
- 1522-6417, 1534-3111
- Tipo:
- Review
- Páginas:
- 57-57
- Factor de Impacto:
- 1,198 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CURRENT HYPERTENSION REPORTS SPRINGER
Citas Recibidas en Web of Science: 3
Documentos
- No hay documentos
Filiaciones
Keywords
- Sleep apnoea; Resistant hypertension; Refractory hypertension; Continuous positive airway pressure
Proyectos asociados
INTENSIFICACION DR. MIGUEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT11/037 . 2012
ASOCIACION ENTRE TRASTORNOS RESPIRATORIOS DEL SUEÑO Y TASA DE CRECIMIENTO DEL MELANOMA CUTANEO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI12/01363 . INSTITUTO DE SALUD CARLOS III . 2013
EFECTO DEL TRATAMIENTO CON CPAP SOBRE LAS CIFRAS TENSIONALES EN PACIENTES CON HIPERTENSION ARTERIAL REFRACTARIA. ESTUDIO MULTICENTRICO Y ALEATORIZADO. ESTUDIO HIPARCO
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI09/01647 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010
INTENSIFICACION DR. MIGUEL ANGEL MARTINEZ GARCIA
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
INT14/00003 . INSTITUTO DE SALUD CARLOS III . 2015
ASOCIACIÓN ENTRE LOS TRASTORNOS RESPIRATORIOS DEL SUEÑO Y EL PRONÓSTICO DEL MELANOMA. ESTUDIO LONGITUDINAL Y MULTICÉNTRICO EN 443 PACIENTES CON MELANOMA CUTÁNEO MALIGNO.
Investigador Principal: MIGUEL ÁNGEL MARTÍNEZ GARCÍA
PI16/01772 . INSTITUTO DE SALUD CARLOS III . 2017
ESTUDIO EPIDEMIOLÓGICO PROSPECTIVO PARA ESTIMAR EL IMPACTO DE LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD EN LA POBLACIÓN ADULTA DEBIDA A STREPTOCOCCUS PNEUMONIAE, MEDIANTE EL USO DE UN NUEVO TEST DIAGNÓSTICO DE DETECCIÓN DEL ANTÍGENO NEUMOCÓCICO ESPECÍFICO DE SEROTIPO EN ORINA (ESTUDIO CAPA).
Investigador Principal: ROSARIO MENÉNDEZ VILLANUEVA
PFI-PRE-2011-02 . 2011
ESTUDIO ORBE. ESTUDIO OBSERVACIONAL RESTROSPECTIVO PARA CARACTERIZAR A LOS PACIENTES QUE RECIBIERON BENRALIZUMAB EN EL MARCO DE UN PROGRAMA DE USO EN CONDICIONES ESPECIALES DE DISPENSACIÓN EN ESPAÑA.
Investigador Principal: ENRIQUE ZALDIVAR OLMEDA
AST-BEN-2018-01
Cita
Oscullo G,Sapina E,Torres G,Zaldivar E,Barbe F,Martinez MA. The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension. Curr Hypertens Rep. 2019. 21(8):p. 57-57. IF:3,856. (2).